TEVA Gears Up to Report Q4 Earnings: What's in the Cards?
Scandal-Ridden Teva Pharmaceutical Is Fishing for a Bottom | Nasdaq
Shlomo Yanai, incoming president and CEO of Teva Pharmaceutical Industries, Ltd., takes part in the opening bell ceremonies at the NASDAQ in New York on February 21, 2007. (UPI Photo/Laura Cavanaugh Stock